The world’s most lucrative healthcare market is quickly appreciating Aussie pharmaceuticals company Pharmaxis (ASX: PXS) whose cystic fibrosis (CF) treatment Bronchitol is rapidly emerging as the preferred treatment by CF sufferers in the United States.
https://www.thesentiment.com.au/pharmaxis-sales-thriving-in-us-following-fda-approval-for-cystic-fibrosis-treatment/
